Abstract:
PROBLEM TO BE SOLVED: To provide a 1,4-disubstituted piperazine derivative of high optical purity having valuable pharmacological activity, particularly antihistaminic activity, and to provide an intermediate for producing the above derivative. SOLUTION: This 1,4-disubstituted piperazine derivative is obtained by reaction under heating of an enantiomer of 1-[(4-chlorophenyl)]piperazine with a halide of the formula: RX [R is methyl, (3-methylphenyl)methyl or the like; and X is a halogen atom]. The other objective method for producing the above derivative is provided as described above.
Abstract:
PROBLEM TO BE SOLVED: To provide an efletirizine which is a pharmaceutical having excellent antihistaminic properties, namely, a new crystal form of a 2-[2-[4-[bis (4-fluorophenyl) methyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride, and to provide a method for preparation of the crystal and to a pharmaceutical composition comprising the same. SOLUTION: The invention relates to the new pseudopolymorphic forms of 2-[2-[4-[bis(4- fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride, defined by the X-ray diffraction pattern, namely, anhydrous 2-[2-[4-[bis(4-fluorophenyl)methyl]-l-piperazinyl]ethoxy]acetic acid dihydrochloride and a monohydrate of the crystal, and relates to the method for preparation of the pseudopolymorphic crystal. The invention also relates to the pharmaceutical composition comprising the pseudopolymorphic crystal, slow release excipient and a cyclodextrine. COPYRIGHT: (C)2007,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide a 1,4-disubstituted piperazine derivative of high optical purity having valuable pharmacological activity and especially antihistamine activity and to provide its production intermediate. SOLUTION: There is provided compounds with the optical purity of higher than 98% selected from the group consisting of a levorotatory dihydrochloride of 1-[(4-chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine, a dextrorotatory dihydrochloride of 1-[(4-chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine or the like. COPYRIGHT: (C)2007,JPO&INPIT
Abstract:
The present invention relates to new pseudopolymorphic forms of 2-[2-[4-[bis (4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride, namely, anhydrous 2-[2-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride and 2-[2-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride monohydrate. It also relates to processes for the preparation of these pseudopolymorphic forms and to pharmaceutical compositions containing them.
Abstract:
In the present invention, there are disclosed novel pseudopolymorphic forms of 2-[2-[4-[bis (4-fluorophenyl) methyl]-1-piperazinyl] ethoxy]acetic acid dihydrochloride, namely, anhydrous 2-[2-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride and 2-[2-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride monohydrate. The invention also relates to processes for the preparation of these pseudopolymorphic forms and to pharmaceutical compositions containing them.
Abstract:
The present invention relates to new pseudopolymorphic forms of 2-Ä2-Ä4-Äbis(4-fluorophenyl)methylÜ-1-piperazinylÜethoxyÜacetic acid dihydrochloride, namely, anhydrous 2-Ä2-Ä4-Äbis(4-fluorophenyl)methylÜ-1-piperazinylÜethoxyÜacetic acid dihydrochloride and 2-Ä2-Ä4-Äbis(4-fluorophenyl)methylÜ-1-piperazinylÜethoxyÜacetic acid dihydrochloride monohydrate. It also relates to processes for the preparation of these pseudopolymorphic forms and to pharmaceutical compositions containing them.
Abstract:
The present invention relates to novel substituted [2-(1-piperazinyl)-ethoxy]methyl compounds of the general formula I, in which Ri1 represents the -CONHi2, -CN, -COOH, -COOM or -COORi3, group, M denotes an alkali metal and Ri3 represents an alkyl radical having from 1 to 4 carbon atoms; and Ri2 represents a hydrogen atom or a group -COR4 or -R5, where Ri4 is selected from the groups --ORi6 or -Ri7, in which Ri5 represents an alkyl or alkylaryl radical, Ri6 represents a linear or branched alkyl radical having from 1 to 4 carbon atoms, a haloalkyl, alkylaryl, alkylnitroaryl or alkylhaloaryl radical, andRi7 represents a haloalkyl radical. The invention further relates to a process for the preparation of the above-indicated compounds, as well as to their use for the preparation of compounds which are themselves valuable intermediates for the preparation of 2-[2-[4[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid or 2-[2-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]-acetic acid and/or pharmaceutically acceptable salts thereof.
Abstract:
PCT No. PCT/BE97/00038 Sec. 371 Date Oct. 9, 1998 Sec. 102(e) Date Oct. 9, 1998 PCT Filed Mar. 28, 1997 PCT Pub. No. WO97/37982 PCT Pub. Date Oct. 16, 1997Novel substituted [2-(1-piperazinyl)ethoxy]methyl compounds. The present invention related to novel substituted [2-(1-piperazinyl)-ethoxy]methyl compounds of formula in which R1 represents a -CONH2, -CN, -COOH, -COOM or -COOR3 group, M being an alkali metal and R3 being an alkyl radical having from 1 to 4 carbon atoms; and R2 represents a hydrogen atom or a group -COR4 or -R5, where R4 is chosen from the groups -OR6 or -R7, in which R5 represents an allyl or alkylaryl radical, R6 represents a linear or branched alkyl radical having from 1 to 4 carbon atoms, a haloalkyl, alkylaryl, alkylnitroaryl or alkylhaloaryl radical, and R7 represents a haloalkyl radical, to a process for the preparation of these compounds, and to their use for the preparation of compounds which are themselves valuable intermediates for the preparation of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid or 2-[2-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]-acetic acid and/or pharmaceutically acceptable salts thereof.
Abstract:
Levorotatory and dextrorotatory enantiomers of 1-[{4-chlorophenyl)phenylmethylj-4-[(4-methylphenyl)sulfonyljpiperazine of the formula their preparation and use for the preparation of substantially optically pur e enantiomers of 1-[(4-chlorophenyl)phenylmethyljpiperazine,. which are themselves valuable intermediate products for the preparation of optically active therapeutic compounds having a very high degree of optical purity.